ERYTECH reports positive top-line Phase III results from clinical study with GRASPA® in Acute Lymphoblastic Leukemia Post author:admERY Post published:September 30, 2014 Post category:Newsroom ERYTECH reports positive Phase III results from its pivotal study with GRASPA® in Acute Lymphoblastic Leukemia. You Might Also Like ERYTECH strengthens its intellectual property position with the issuance of United States patent for erythrocytes containing arginine deiminase September 23, 2015 ERYTECH adds a new product candidate to its Cancer Metabolism development portfolio April 9, 2014 ERYTECH to Host KOL Breakfast Symposium with Audio Webcast on November 7, 2018 November 5, 2018
ERYTECH strengthens its intellectual property position with the issuance of United States patent for erythrocytes containing arginine deiminase September 23, 2015
